Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr 20:41:e9.
doi: 10.26633/RPSP.2017.9.

[Antituberculosis-drug resistance in the border of Brazil with Paraguay and Bolivia]

[Article in Portuguese]
Marli Marques  1 , Eunice Atsuko Totumi Cunha  2 , Maria do Socorro Nantua Evangelista  3 , Paulo Cesar Basta  4 , Ana Maria Campos Marques  5 , Julio Croda  6 , Sonia Maria Oliveira de Andrade  1
Affiliations

[Antituberculosis-drug resistance in the border of Brazil with Paraguay and Bolivia]

[Article in Portuguese]
Marli Marques et al. Rev Panam Salud Publica. .

Abstract
in English, Portuguese

Objective: To estimate the rate of drug resistance among pulmonary tuberculosis (PTB) cases in the state of Mato Grosso do Sul, Brazil, and specifically in the border areas with Paraguay and Bolivia, as well as to identify associated risk factors.

Method: The present cross-sectional, epidemiological study focused on PTB cases recorded between January 2007 and December 2010 in the State Reportable Disease Information System with results of susceptibility tests to rifampicin, isoniazid, ethambutol, and streptomycin. Dependent variables were development of resistance to a single drug or any combination of drugs. Independent variables were being a new or treated case, living in border areas, presence/absence of diabetes, and history of alcoholism.

Results: There were 789 TBP cases with susceptibility testing. The following characteristics were associated with resistance: treated case (P = 0.0001), border region (P = 0.0142), alcoholism (P = 0.0451), and diabetes (P = 0.0708). The rates of combined, primary, and acquired resistance for the state were 16.3%, 10.6%, and 39.0%, vs. 22.3%, 19.2%, and 37.5% for the border region. The rates of combined, primary, and acquired multidrug resistance for the state were 1.8%, 0.6%, and 6.3%, vs. 3.1%, 1.2%, and 12.5% for the border region.

Conclusions: In the border region, the state should investigate drug resistance in all patients with respiratory symptoms, determine the pattern of resistance in confirmed cases, adopt directly observed treatment for cases of PTB, and develop health actions together with neighboring countries. Across the state, the levels of acquired resistance should be monitored, with investigation of resistance in all treated cases and implementation of directly observed treatment especially among patients with diabetes or alcoholism.

Objetivo.: Estimar as taxas de resistência às drogas entre casos de tuberculose pulmonar (TBP) para o estado de Mato Grosso do Sul, Brasil, e especificamente para a região da fronteira com Paraguai e Bolívia, além de identificar fatores de risco associados.

Métodos.: O presente estudo epidemiológico, transversal, enfocou os casos de TBP registrados de janeiro de 2007 a dezembro de 2010 no Sistema de Informação de Agravos de Notificação da Secretaria de Estado de Saúde com resultados do teste de suscetibilidade a rifampicina, isoniazida, etambutol e estreptomicina. Definiram-se como variáveis dependentes o desenvolvimento de resistência a uma única droga e a qualquer combinação de drogas. As variáveis independentes foram ser caso novo ou tratado, residência em região de fronteira ou outra região, presença ou ausência de diabetes e história de alcoolismo.

Resultados.: Foram identificados 789 casos de TBP com teste de suscetibilidade. As características associadas à resistência foram: caso tratado (P=0,0001), região de fronteira (P=0,0142), alcoolismo (P=0,0451) e diabetes (P=0,0708). As taxas de resistência combinada, primária e adquirida no estado foram de 16,3%, 10,6% e 39,0%, e na fronteira, de 22,3%, 19,2% e 37,5%. As taxas de resistência a múltiplas drogas combinada, primária e adquirida no estado foram de 1,8%, 0,6% e 6,3%, e na fronteira, de 3,1%, 1,2% e 12,5%.

Conclusões.: O estado deve, na região de fronteira, realizar cultura em todos os sintomáticos respiratórios, investigar o padrão de resistência nos casos confirmados, adotar o tratamento diretamente observado nos casos de TBP e desencadear ações de saúde conjuntas com os países fronteiriços. Em todo o estado, é necessário monitorar os níveis de resistência adquirida, ampliar a investigação de resistência para todos os casos tratados e adotar o tratamento diretamente observado prioritariamente entre pacientes com alcoolismo e diabetes.

PubMed Disclaimer

Conflict of interest statement

Conflitos de interesse. Nada declarado pelos autores.

Similar articles

See all similar articles

Cited by

References

    1. Lehmann J. Twenty years afterward. Historical notes on the discovery of the antituberculosis effect of para-aminosalicylic acid (PAS) and the first clinical trials. Am Rev Respir Dis. 1964;90:953–956. - PubMed
    2. 1. Lehmann J. Twenty years afterward. Historical notes on the discovery of the antituberculosis effect of para-aminosalicylic acid (PAS) and the first clinical trials. Am Rev Respir Dis. 1964;90: 953–6. - PubMed
    1. Long ER, Ferebee SH. A controlled investigation of streptomycin treatment in pulmonary tuberculosis. Public Health Resp. 1950;65(44):1421–1451. - PubMed
    2. 2. Long ER, Ferebee SH. A controlled investigation of streptomycin treatment in pulmonary tuberculosis. Public Health Resp. 1950;65(44):1421–51. - PubMed
    1. Pablos-Mendes A, Raviglione MC, Laszlo A, Binkin N, Rieder HI, Bustreo F, et al. Global surveillance for antituberculosis-drug resistance, 1994–1997. World Health Organization – International Union against Tuberculosis and Lung Disease Working Group on Anti-tuberculosis Drug Resistance Surveillance. N Engl J Med. 1998;338(23):1641–1649. - PubMed
    2. 3. Pablos-Mendes A, Raviglione MC, Laszlo A, Binkin N, Rieder HI, Bustreo F, et al. Global surveillance for antituberculosis-drug resistance, 1994–1997. World Health Organization – International Union against Tuberculosis and Lung Disease Working Group on Anti-tuberculosis Drug Resistance Surveillance. N Engl J Med. 1998;338(23):1641–9. - PubMed
    1. World Health Organization The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. [Report no. 4. WHO/HTM/TB/2008.394] Antituberculosis drug resistance in the world. 2008 Genebra: WHO.
    2. 4. World Health Organization. The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Antituberculosis drug resistance in the world. Genebra: WHO; 2008 [Report no. 4. WHO/HTM/TB/2008.394].
    1. Goble M, Iseman MD, Masden LA, Waite D, Ackerson L, Horsburgh CR., Jr Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med. 1993;328(8):527–532. - PubMed
    2. 5. Goble M, Iseman MD, Masden LA, Waite D, Ackerson L, Horsburgh CR Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med. 1993;328(8):527–32. - PubMed

Substances

LinkOut - more resources